Julie Zhen Qin Wu

Array ( [id] => 11668479 [patent_doc_number] => 20170157199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/433887 [patent_app_country] => US [patent_app_date] => 2017-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 26965 [patent_no_of_claims] => 71 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15433887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977639 [patent_doc_number] => 20170281793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'ANTI-TEM1 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/411938 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 29617 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336569 [patent_doc_number] => 10787514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => CD33 antibodies and use of same to treat cancer [patent_app_type] => utility [patent_app_number] => 15/411947 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 18786 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837515 [patent_doc_number] => 20190022242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => NOVEL ANTI-MMP16 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/065059 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826655 [patent_doc_number] => 20190016812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/065063 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13774861 [patent_doc_number] => 20190000969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => NOVEL ANTI-UPK1B ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/065064 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622135 [patent_doc_number] => 20180362619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => VARIANT ANTIBODIES FOR SITE-SPECIFIC CONJUGATION [patent_app_type] => utility [patent_app_number] => 16/061646 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11956102 [patent_doc_number] => 20170260253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/357545 [patent_app_country] => US [patent_app_date] => 2016-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 31991 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15357545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16183544 [patent_doc_number] => 10716837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-21 [patent_title] => Methods and compositions relating to P62 for the treatment and prophylaxis of cancer [patent_app_type] => utility [patent_app_number] => 15/340118 [patent_app_country] => US [patent_app_date] => 2016-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 12420 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15340118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604394 [patent_doc_number] => 20170121693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'NUCLEOBASE EDITORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/331852 [patent_app_country] => US [patent_app_date] => 2016-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 138 [patent_no_of_words] => 77935 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443251 [patent_doc_number] => 20170044271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'NOVEL ANTI-DPEP3 ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/331282 [patent_app_country] => US [patent_app_date] => 2016-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 48479 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504785 [patent_doc_number] => 20180303935 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => A NANOMATERIAL COMPLEX COMPRISING GRAPHENE OXIDE ASSOCIATED WITH A THERAPEUTIC AGENT AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/768700 [patent_app_country] => US [patent_app_date] => 2016-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22843 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11556148 [patent_doc_number] => 20170102394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'METHOD TO OPTIMIZE THE TREATMENT OF PATIENTS WITH BIOLOGICAL DRUGS' [patent_app_type] => utility [patent_app_number] => 15/281829 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12194 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15281829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440521 [patent_doc_number] => 20180271803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF ORAL MUCOSITIS [patent_app_type] => utility [patent_app_number] => 15/757281 [patent_app_country] => US [patent_app_date] => 2016-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15757281 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11492643 [patent_doc_number] => 20170066829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'PRODUCTION OF HERSINTUZUMAB: A NEW HUMANIZED ANTIBODY AGAINST HER2 FOR CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 15/249910 [patent_app_country] => US [patent_app_date] => 2016-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4951 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15249910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11514346 [patent_doc_number] => 20170081419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'NOVEL MODULATORS AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/250151 [patent_app_country] => US [patent_app_date] => 2016-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 52680 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15250151 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11270562 [patent_doc_number] => 20160333109 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-17 [patent_title] => 'ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS' [patent_app_type] => utility [patent_app_number] => 15/227565 [patent_app_country] => US [patent_app_date] => 2016-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 23780 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15227565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11422769 [patent_doc_number] => 20170030913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'COMPOSITION OR KIT FOR DIAGNOSING COLORECTAL CANCER INCLUIDNG CXCL7-MEASURING AGENT AND METHOD OF DIAGNOSING COLORECTAL CANCER USING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/220521 [patent_app_country] => US [patent_app_date] => 2016-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 3245 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15220521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14945865 [patent_doc_number] => 10434180 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-08 [patent_title] => Enzymatic conjugation of polypeptides [patent_app_type] => utility [patent_app_number] => 15/214331 [patent_app_country] => US [patent_app_date] => 2016-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 50 [patent_no_of_words] => 67455 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 214 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15214331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11469735 [patent_doc_number] => 20170056519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'Fusion proteins for treating pathological blood clots' [patent_app_type] => utility [patent_app_number] => 15/212305 [patent_app_country] => US [patent_app_date] => 2016-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 25428 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15212305 [rel_patent_id] =>[rel_patent_doc_number] =>)